In an adult presenting with loud snoring, witnessed apneas, frequent nocturnal awakenings, excessive daytime sleepiness, obesity or a neck circumference > 17 inches in men or > 16 inches in women, how should obstructive sleep apnea (OSA) be suspected, confirmed with polysomnography (including apnea‑hypopnea index thresholds), and managed (first‑line continuous positive airway pressure (CPAP) and adjunctive therapies)?

Obstructive Sleep Apnea: Clinical Suspicion, Diagnostic Confirmation, and Management

Adults presenting with loud snoring, witnessed apneas, frequent nocturnal awakenings, excessive daytime sleepiness, obesity, or neck circumference >17 inches (men) or >16 inches (women) should undergo polysomnography for definitive diagnosis, with OSA confirmed by AHI ≥5/hour with symptoms or AHI ≥15/hour without symptoms, and treated first-line with continuous positive airway pressure (CPAP) therapy. 1, 2, 3

Clinical Suspicion and Risk Assessment

When to Suspect OSA:

• Suspect OSA in patients presenting with the classic triad: habitual loud snoring, witnessed apneas/gasping/choking during sleep, and excessive daytime sleepiness 3, 4, 5
• Additional symptoms warranting evaluation include frequent nocturnal awakenings, morning headaches, nocturia, chronic fatigue, and unrefreshing sleep 3, 6, 7
• Critical pitfall: 78% of patients with polysomnography-confirmed OSA denied common symptoms of snoring and sleepiness, so absence of reported symptoms does not exclude the diagnosis 8, 2

High-Risk Physical Findings:

• Neck circumference ≥17 inches in men or ≥16 inches in women indicates substantially increased OSA risk 8, 2, 5
• Obesity (particularly BMI >30 kg/m²) is a major risk factor, though OSA occurs even in non-obese individuals 1, 6
• Laterally narrowed oropharynx, tonsillar hypertrophy, and soft palate redundancy contribute to upper airway obstruction 8, 5
• Important caveat: In young adults aged 20-50 years, OSA prevalence can reach 15% even in certain populations, and 84% of non-obese men (BMI ~27 kg/m²) with classic symptoms have confirmed OSA 8

Screening Tools:

• The STOP-BANG questionnaire is the most sensitive screening tool for OSA, though screening accuracy is limited 3
• The U.S. Preventive Services Task Force states there is insufficient evidence to recommend routine screening in asymptomatic patients 3

Diagnostic Confirmation with Polysomnography

Diagnostic Thresholds:

• OSA is diagnosed when AHI ≥5 events/hour in the presence of symptoms (excessive daytime sleepiness, witnessed apneas, nocturnal gasping/choking, morning headaches, nocturia, or chronic fatigue) 1, 2, 3
• OSA is diagnosed when AHI ≥15 events/hour even without symptoms, reflecting cardiovascular risk independent of subjective complaints 2, 3
• In patients with cardiovascular or cerebrovascular disease, AHI ≥5 events/hour is clinically significant regardless of symptom presence 2

Severity Classification After Diagnosis:

• Mild OSA: AHI 5-15 events/hour 2
• Moderate OSA: AHI 15-30 events/hour 2
• Severe OSA: AHI ≥30 events/hour 2

Respiratory Event Definitions:

• A hypopnea is scored when peak airflow drops ≥30% from baseline for ≥10 seconds AND is accompanied by either ≥3% oxygen desaturation OR an EEG-documented arousal 1, 2
• Critical distinction: The Centers for Medicare and Medicaid Services uses a ≥4% desaturation threshold without arousal criteria, which can underdiagnose OSA by 36-48% and reduce median AHI from ~25 events/hour to ~8 events/hour in the same patient 2
• The Respiratory Disturbance Index (RDI) includes respiratory effort-related arousals (RERAs) and may detect clinically significant disease missed by AHI alone, particularly in lean patients with minimal desaturations; RDI ≥5 events/hour is diagnostic 2

Polysomnography Requirements:

• In-laboratory polysomnography (Type I) is the gold standard and must include EEG for sleep staging and arousal detection, EOG, chin EMG, airflow monitoring, oxygen saturation, respiratory effort, and ECG 1, 2, 3
• Home sleep apnea testing (Type III) may be used when high pretest probability of moderate-to-severe OSA exists without significant cardiopulmonary comorbidities 2, 3, 7
• Important limitation: Negative home sleep apnea testing requires confirmatory in-laboratory polysomnography due to inability to detect arousal-based events 2

First-Line Management: Continuous Positive Airway Pressure (CPAP)

CPAP Therapy Indications and Benefits:

• CPAP is first-line treatment for moderate to severe OSA (AHI ≥15 events/hour) 2, 3
• CPAP improves sleep quality, reduces AHI, decreases resistant hypertension, reduces cardiac arrhythmias, and decreases daytime sleepiness 2
• Use humidified nasal or facial mask to improve tolerance 3
• Early patient education and support improve adherence rates, which are otherwise variable 3, 7

Follow-Up Polysomnography to Assess Treatment Response:

• Repeat polysomnography after substantial weight loss (≥10% body weight), substantial weight gain with symptom return, insufficient clinical response to CPAP, or surgical/dental treatment for OSA 2

Adjunctive Therapies

Weight Loss:

• Weight reduction through intensive lifestyle modification, medications, or bariatric surgery is a beneficial adjunct to CPAP 3, 7
• Bariatric surgery can improve sleep parameters and symptoms in obese patients with OSA and can result in remission in many patients 7

Blood Pressure Optimization:

• Optimize blood pressure control if hypertensive, as OSA is an independent risk factor for hypertension 2, 6

Alternatives for CPAP Intolerance:

• For patients intolerant of or nonadherent to CPAP, consider changing mask type, mandibular advancement devices, hypoglossal nerve stimulation, or surgical interventions to correct anatomic obstructions 3, 7
• Evidence limitation: Although many OSA therapies effectively improve daytime sleepiness and blood pressure, none have demonstrated a mortality benefit in randomized controlled trials 3

Common Pitfalls to Avoid

• Do not dismiss snoring in young, non-obese individuals as benign—OSA can occur even with normal BMI, particularly in certain ethnic populations 8
• Do not rely solely on patient-reported symptoms—objective sleep testing is required when clinical suspicion exists, as most patients with confirmed OSA deny classic symptoms 8, 2
• Do not continue empiric CPAP therapy without objective confirmation of OSA diagnosis—this delays identification of alternative treatable causes such as narcolepsy, idiopathic hypersomnia, restless legs syndrome, or central sleep apnea 9
• Do not use CMS 4% desaturation criteria alone—this significantly underdiagnoses OSA compared to AASM 3% desaturation or arousal-based criteria 2
• Do not assume negative home sleep apnea testing excludes OSA—confirmatory in-laboratory polysomnography is required due to inability to detect arousal-based events 2